Jianxiang Wang
Dongbei University of Finance and Economics(CN)Tianjin University of Technology(CN)Nanchang University(CN)Qingdao University of Science and Technology(CN)Guiyang Medical University(CN)Baylor College of Medicine(US)Shanghai Jiao Tong University(CN)Chinese Academy of Medical Sciences & Peking Union Medical College(CN)Peking University(CN)Peking Union Medical College Hospital(CN)Ruijin Hospital(CN)Zhengzhou University(CN)Tianjin Anding Hospital(CN)Affiliated Hospital of Guizhou Medical University(CN)National Clinical Research(US)Shanghai Institute of Hematology(CN)Zhejiang Institute of Mechanical and Electrical Engineering(CN)Institute of Hematology & Blood Diseases Hospital(CN)First Affiliated Hospital of Zhengzhou University(CN)First Affiliated Hospital of Nanchang University(CN)Xi'an Jiaotong University(CN)
Publications by Year
Research Areas
Acute Myeloid Leukemia Research, Chronic Myeloid Leukemia Treatments, Chronic Lymphocytic Leukemia Research, Acute Lymphoblastic Leukemia research, CAR-T cell therapy research
Most-Cited Works
- → Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN(2022)2,782 cited
- → Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia(2020)2,660 cited
- → Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)(2011)602 cited
- → ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex(1998)520 cited
- → Ivosidenib and Azacitidine in IDH1 -Mutated Acute Myeloid Leukemia(2022)463 cited
- → Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy(2021)355 cited